U.S. Patent Granted For Rexahn Pharmaceuticals' Sexual Dysfunction Compound, Zoraxel

Sep 20, 2007

Rexahn Pharmaceuticals Receives Key U.S. Patent for Cancer Compound RX-0047

Jun 28, 2007

Rexahn Pharmaceuticals, Inc. Appoints Dr. Freddie Ann Hoffman to the Board of Directors

Jun 15, 2007

Data from Rexahn Pharmaceuticals' Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago

May 30, 2007

Rexahn Pharmaceuticals Receives FDA Approval to Initiate a Phase II Trial for Archexin in Patients with Renal Cell Carcinoma

May 29, 2007

Rexahn Pharmaceuticals, Inc. to Present at The Robins Group Emerging Opportunities Investment Conference in New York City

May 23, 2007

R&D Directions Magazine Names Rexahn's Leading Cancer Candidate, RX-0201 (Archexin) among ''100 Great Investigational Drugs''

Apr 5, 2007

Rexahn Pharmaceuticals Engages Catalyst Financial Resources

Mar 19, 2007

Rexahn Awarded Maryland Industrial Partnerships Grant to Develop Targeted Nano-Polymer Cancer Drugs

Mar 6, 2007

Rexahn Signs Agreement with National Institute of Neurological Disorders and Stroke

Feb 5, 2007